The goal of the ADRC HS Scholars Program is to reach talented young people from backgrounds underrepresented in science and medicine, and to encourage and inspire them toward careers in these fields.
Adam M. Brickman, PhD, Professor of Neuropsychology, and Scott A. Small, MD, Boris and Rose Katz Professor of Neurology, discuss their study that examined health benefits of flavanol-rich diet
Scott Small, MD, Boris & Rose Katz Professor of Neurology and Director & Alzheimer's Disease Research Center at CUIMC talks about the study that examined flavanols levels and memory loss
Many people live years or even decades with dementia, which causes death. Researching the symptoms and causes can dramatically help dementia care and prevention.
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
On Monday, the FDA approved a new drug for Alzheimer’s disease—the first in nearly two decades. Biogen’s aducanumab aims to slow the cognitive decline often associated with the disease.
Other researchers are not convinced that these biomarkers vary by race, primarily because so little Alzheimer’s research has been conducted on Black and Latinx people.